Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial
Open Access
- 31 January 2015
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 13 (5) , 743-754
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk A/S, Bagsværd, Denmark
This publication has 24 references indexed in Scilit:
- Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia BThrombosis Research, 2013
- Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patientsBlood, 2012
- Guidelines for the management of hemophiliaHaemophilia, 2012
- Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patientsBlood, 2012
- Venous access in haemophilic children: choice and managementHaemophilia, 2010
- Prophylactic therapy in haemophiliaBlood Reviews, 2009
- Tissue factor pathway inhibitor: structure, biology and involvement in diseaseThe Journal of Pathology, 2005
- Barriers to compliance with prophylaxis therapy in haemophiliaHaemophilia, 2001
- The Hemophilias — From Royal Genes to Gene TherapyNew England Journal of Medicine, 2001
- Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and BJournal of Internal Medicine, 1992